Medtronic Puts $700 Million Into Surgical Robot Maker Cornerstone Robotics
The medical device giant is buying into a second robotic surgery platform to give hospitals more choice and reach markets where its own system has not yet landed.
Key points
- Medtronic announced a $700 million investment in the Hong Kong-based surgical robotics firm on the day of publication.
- The partner company's Sentire surgical robot has regulatory approval in China, the European Union, and Singapore as of May 2026.
- Medtronic's own Hugo system is now used in more than 35 countries and received FDA clearance in the United States within the past year.
- Medtronic expects Hugo to exceed 50,000 total procedures globally by the end of its current fiscal year.
- The deal makes Medtronic the only company offering two separate robotic surgery platforms as a combined portfolio.
Medtronic, the Minneapolis-based medical device company, has agreed to invest $700 million in Hong Kong-based surgical robotics firm Cornerstone Robotics and will distribute its Sentire surgical system in approved markets outside the United States. First reported by The Robot Report, the deal gives Medtronic a second robotic surgery product alongside its existing Hugo system. We covered Medtronic's AI platform for smarter surgeries on 22 July 2026, and this investment is the next structural move in the same build-out.
Robotic surgery systems let surgeons operate through small incisions using joystick-style controls and a magnified 3D camera view, rather than opening a patient with a large cut. Shorter recovery times make them increasingly popular for soft-tissue procedures in gynaecology and urology.
Why does Medtronic need two robots?
Different hospitals want different things. Some need a familiar control layout; others need a system that already has local regulatory sign-off. "Surgeons, health systems and markets have varying needs and preferences, which is why we are investing across robotic platforms, digital tools and platform-enhancing technologies," said Matt Anderson, Medtronic's senior vice president and president of surgical, in a statement to The Robot Report.
Sentire received its CE Mark, the European safety and performance certification, in May 2026 for minimally invasive general surgery, gynaecology, thoracic (chest) surgery and urology. Developed entirely in-house by the company's team, it has completed multi-specialty clinical trials and carries approvals in China and Singapore as well.
Hugo is available in more than 35 countries across six continents. Its procedure growth rate is currently more than double the broader robotic surgery market's rate, according to Medtronic. The company expects Hugo to top 50,000 procedures globally before its fiscal year closes.
What does this mean for patients?
More hospitals accessing a robotic system generally means more patients benefit from smaller incisions. Neither Sentire nor Hugo is sold directly to consumers; both go to hospitals and surgical centres.
Surgeons at institutions in Europe and Asia may soon see Sentire appear as an option alongside Hugo. Patients should ask their surgeon which system will be used and whether it carries local regulatory approval.
Medtronic's software roadmap for Hugo includes real-time AI assistance and expanded surgical instruments. It's a platform the company is clearly not standing still on.
| Platform | Maker | Approved markets | Procedures (est.) |
|---|---|---|---|
| Hugo RAS | Medtronic | 35+ countries, including US | ~50,000 by end FY2026 |
| Sentire | Cornerstone Robotics | EU, China, Singapore | Post-trial phase |
What happens next?
Distribution of Sentire in approved markets outside the US begins now, alongside continued Hugo expansion. Separately, Medtronic invested $80 million in Pi-Cardia, a heart valve technology firm, that same week. The honest read: Medtronic's two-platform strategy is a hedge, and the real test is whether Sentire finds traction in the markets where Hugo hasn't.
